The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
After treatment, the concentration of total testosterone in serum decreases, and the acne score is significantly lower than before treatment (77)
The pulmonary hypertension findings deserve special attention
I went from 173 lbs down to 138
Table of Contents What Is Retatrutide and Its Role in Weight Loss Treatment Understanding Retatrutide Reconstitution: Important Safety Information Reconstitution Calculators: Why They Are Not Appropriate for Patient Use Dosing Considerations and MHRA Safety Guidance Risks of Incorrect Reconstitution and When to Seek Advice Accessing Weight Loss Medicines Safely Through UK Healthcare Scientific References Frequently Asked Questions What Is Retatrutide and Its Role in Weight Loss Treatment Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed by the MHRA or EMA, meaning it cannot legally be prescribed or supplied as a medicine in the UK outside approved clinical trials
Yes, compromised storage that allows temperature fluctuations can reduce peptide potency and diminish appetite-suppression and metabolic effects